Abstract
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that is currently validated for treatment and has shown survival benefit in various cancers, particularly non-small cell lung cancer. However, a very specific toxicity profile has been observed with bevacizumab. This article presents data from the literature concerning hypertension and proteinuria, and provides recommendations for the management of these toxicities.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Clinical Trials, Phase III as Topic
-
Humans
-
Hypertension / chemically induced*
-
Hypertension / drug therapy
-
Hypertension / epidemiology
-
Incidence
-
Lung Neoplasms / drug therapy*
-
Meta-Analysis as Topic
-
Proteinuria / chemically induced*
-
Proteinuria / diagnosis
-
Proteinuria / epidemiology
-
Risk
-
Time Factors
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Bevacizumab